Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Yuliya Sharkovska"'
Autor:
Ina M Ott, Markus L Alter, Karoline von Websky, Axel Kretschmer, Oleg Tsuprykov, Yuliya Sharkovska, Katharina Krause-Relle, Jens Raila, Andrea Henze, Johannes-Peter Stasch, Berthold Hocher
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e42623 (2012)
The prevalence of diabetes mellitus and its complications, such as diabetic nephropathy (DN), is rising worldwide and prevention and treatment are therefore becoming increasingly important. Therapy of DN is particularly important for patients who do
Externí odkaz:
https://doaj.org/article/a6202658b37c4c4399ca255f1e4e9112
Autor:
Sandra Geschka, Axel Kretschmer, Yuliya Sharkovska, Oleg V Evgenov, Bettina Lawrenz, Andreas Hucke, Berthold Hocher, Johannes-Peter Stasch
Publikováno v:
PLoS ONE, Vol 6, Iss 7, p e21853 (2011)
A direct pharmacological stimulation of soluble guanylate cyclase (sGC) is an emerging therapeutic approach to the management of various cardiovascular disorders associated with endothelial dysfunction. Novel sGC stimulators, including riociguat (BAY
Externí odkaz:
https://doaj.org/article/1d623c71c2444c6888f0ee1708eac1bb
Autor:
Till Scheuer, Christoph Bührer, Elena auf dem Brinke, Vivien Friedrich, Stefanie Endesfelder, Imre Vida, Yuliya Sharkovska, Thomas Schmitz, Sabine Grosser, Daniele Mattei, Paula Charlotte Barthel, Susanne A. Wolf
Publikováno v:
Development (Cambridge, England). 148(20)
The inhibitory GABAergic system in the brain is involved in the etiology of various psychiatric problems, including autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD) and others. These disorders are influenced not only b
Autor:
Ina Ott, Katharina Krause-Relle, Axel Kretschmer, Karoline von Websky, Berthold Hocher, Yuliya Sharkovska, Jens Raila, Johannes-Peter Stasch, Andrea Henze, Markus Alter, Oleg Tsuprykov
Publikováno v:
BMC Pharmacology
Background Riociguat is the first of a new class of drugs, the soluble guanylate cyclase (sGC) stimulators. Riociguat has a dual mode of action: it sensitizes sGC to the body’s own NO and can also increase sGC activity in the absence of NO. The NO-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11cb35a636155bc3df3e9e0e4e5b8c88
Autor:
Markus Alter, Thomas Klein, Oleg Tsuprykov, Thomas Secher, Berthold Hocher, Christoph Reichetzeder, Yuliya Sharkovska, Sebastian Bachmann
Publikováno v:
Journal of Hypertension. 32:2211-2223
Background: Despite the beneficial effects of type 4 dipeptidyl peptidase (DPP-4) inhibitors on glucose levels, its effects on diabetic nephropathy remain unclear. Method: This study examined the long-term renoprotective effects of DPP-4 inhibitor li
Autor:
Stefanie Endesfelder, Yuliya Sharkovska, Thomas Schmitz, Katharina Marggraf, Victor Tarabykin, Vivien Brockmöller, Till Scheuer, Christoph Bührer
Publikováno v:
Molecular Neurobiology.
Impaired postnatal brain development of preterm infants often results in neurological deficits. Besides pathologies of the forebrain, maldeveolopment of the cerebellum is increasingly recognized to contribute to psychomotor impairments of many former
Autor:
Anders Hallberg, Dilyara Lauer, Manuela Sommerfeld, Björn Dahlöf, Ulrich Kintscher, Thomas Unger, Christa Thöne-Reineke, Svetlana Slavic, Ulrike Muscha Steckelings, Elena Kaschina, Yuliya Sharkovska
Publikováno v:
Hypertension, 63(3), E60-E67. LIPPINCOTT WILLIAMS & WILKINS
Lauer, D, Slavic, S, Sommerfeld, M, Thöne-Reineke, C, Sharkovska, Y, Hallberg, A, Dahlöf, B, Kintscher, U, Unger, T, Steckelings, U M & Kaschina, E 2014, ' Angiotensin Type 2 Receptor Stimulation Ameliorates Left Ventricular Fibrosis and Dysfunction via Regulation of Tissue Inhibitor of Matrix Metalloproteinase 1/Matrix Metalloproteinase 9 Axis and Transforming Growth Factor β1 in the Rat Heart ', Hypertension, vol. 63, no. 3, pp. e60-e67 . https://doi.org/10.1161/HYPERTENSIONAHA.113.02522
Lauer, D, Slavic, S, Sommerfeld, M, Thöne-Reineke, C, Sharkovska, Y, Hallberg, A, Dahlöf, B, Kintscher, U, Unger, T, Steckelings, U M & Kaschina, E 2014, ' Angiotensin Type 2 Receptor Stimulation Ameliorates Left Ventricular Fibrosis and Dysfunction via Regulation of Tissue Inhibitor of Matrix Metalloproteinase 1/Matrix Metalloproteinase 9 Axis and Transforming Growth Factor β1 in the Rat Heart ', Hypertension, vol. 63, no. 3, pp. e60-e67 . https://doi.org/10.1161/HYPERTENSIONAHA.113.02522
Left ventricular (LV) remodeling is the main reason for the development of progressive cardiac dysfunction after myocardial infarction (MI). This study investigated whether stimulation of the angiotensin type 2 receptor is able to ameliorate post-MI
Publikováno v:
International Journal of Cardiology. 167:87-93
article i nfo Background: Dipeptidylpeptidase-4 inhibition is reported to have beneficial effects on myocardial ischemia. Mechanisms might include a reduced degradation of stromal cell-derived factor-1 alpha with subsequent increased recruitment of c
Autor:
Seiya Okuda, Viktoriia Antonenko, Ahmed A. Hasan, Markus Alter, Ryotaro Ando, Harald Tammen, Karoline von Websky, Lyubov Chaykovska, Christoph Reichetzeder, Yuliya Sharkovska, Oleg Tsuprykov, Berthold Hocher, Sho-ichi Yamagishi, Thomas Klein, Seiji Ueda, Jan Rahnenführer
Dipeptidyl peptidase (DPP)-4 inhibitors delay chronic kidney disease (CKD) progression in experimental diabetic nephropathy in a glucose-independent manner. Here we compared the effects of the DPP-4 inhibitor linagliptin versus telmisartan in prevent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d38693a0465a158c1d0fb6290082aa20
https://publishup.uni-potsdam.de/frontdoor/index/index/docId/45388
https://publishup.uni-potsdam.de/frontdoor/index/index/docId/45388
Autor:
Ina M. Ott, Oleg Tsuprykov, Katharina Krause-Relle, Thomas Klein, Markus Alter, Berthold Hocher, Yuliya Sharkovska, Jens Raila, Karoline von Websky, Andrea Henze
Publikováno v:
Kidney and Blood Pressure Research. 36:119-130
Background: The need for an improved treatment for diabetic nephropathy is greatest in patients who do not adequately respond to angiotensin II receptor blockers (ARBs). This study investigated the effect of the novel dipeptidyl peptidase-4 inhibitor